Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Randomized, Open-label Clinical Trial of Daily Myrcludex B Versus Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

NCT02881008 is registered in ClinicalTrials.gov with Hepatera Ltd. as lead sponsor.

NCT NCT02881008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02881008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Randomized, Open-label Clinical Trial of Daily Myrcludex B Versus Entecavir in Patients With HBeAg Negative Chronic Hepatitis B
Lead sponsor
Hepatera Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
November 14, 2012
Completion date
October 4, 2014
Enrollment
48 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b